ED90 Determination of Carbetocin for the Prevention of Uterine Atony in Women Undergoing an Elective Cesarean Delivery

• Status: Unknown status
• Trial end date: 2013-03-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this trial is to determine the effective dose of carbetocin which would prevent the occurrence of postpartum uterine atony in 90% of women undergoing an elective cesarean delivery.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Maisonneuve-Rosemont Hospital
• Collaborator: Université de Montréal
• Treatments: Carbetocin; Oxytocin

Criteria

Inclusion Criteria:

• Healthy pregnant women (ASA I or II)

• Elective cesarean delivery

• Spinal anesthesia

• Term gestation (37 weeks and above)

Exclusion Criteria:

• Multiple gestation

• Known coagulopathy

• Active labour

• Uterine fibroids

• Body mass index > 45

• Emergency cesarean section

• General anesthesia

• Any contraindication to neuraxial anesthesia

• Cardiopathies

• Known allergies to carbetocin

• Patient refusal

• Placenta previa/Placenta accreta

• Hypertensive disease/Preeclampsia/Eclampsia

• Polyhydramnios

• Previous history of uterine atony or postpartum hemorrhage

• Renal or liver disease